EYPT EyePoint Pharmaceuticals Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
20:26
Aug 17
Aug 17
Bloomberg Markets
EyePoint trial failure drives record drop.
EyePoint shares had a record drop after its experimental wet age-related macular degeneration treatment failed the primary goal in a late-stage trial, and Cantor cut the stock to neutral, calling the failure a scenario they had not contemplated.
EYPT
EyePoint Pharmaceuticals Inc.
Avoid
—
—
About EYPT Investor Commentary
Across the available history and selected sources, Buzzberg tracks EYPT (EyePoint Pharmaceuticals Inc.) across 4 sources: 0 bullish vs 0 bearish calls from 4 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 7 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: Joe Deaux.